ClinicalTrials.gg
CompletedNCT00734162Updated Sep 1, 2016Results posted

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

A Phase 3 interventional study of Tenofovir disoproxil fumarate (TDF) and Placebo in Hepatitis B Virus (HBV), sponsored by Gilead Sciences. Completed at 21 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-01.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
30th of 50
106 · median 117
Started
2008
with 6 others
Phase 3
13 of 50
none open now
Registered
10th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 30th largest by enrollment, is one of 7 that started in 2008, is one of 13 in phase 3, and was the 10th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.

The optimal treatment for adolescents with chronic HBV infection is currently unknown. Treatment with interferon alfa, lamivudine, and adefovir dipivoxil in pediatric populations has been shown to be less than optimal. Further, the safety and efficacy of entecavir and telbivudine have not been established in patients \< 16 years of age. A study evaluating TDF in adolescents (ages 12-17) was needed to assess the safety and efficacy of this agent in the treatment of chronic hepatitis B in this patient population. In addition, the study will help to further elucidate the pharmacokinetic (PK) and resistance profiles of TDF. Through their participation, study participants will help generate critical new information to help guide the most optimal treatment of chronic HBV infection in adolescents.

This is a randomized, double-blind study to evaluate the antiviral efficacy, safety, and tolerability of TDF versus placebo in adolescents with chronic HBV infection. TDF treatment-naive participants were randomized in a 1:1 ratio to TDF or placebo. After 72 weeks of blinded treatment, participants were to switch to open-label TDF for an additional 2.5 years of treatment, provided that no safety concerns are identified by the Independent Data Monitoring Committee monitoring the study.

03

Conditions studied

  • Hepatitis B Virus (HBV)

Browse trials for

Keywords

  • tenofovir
  • adolescents
  • chronic hepatitis B
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 106 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 12 through 17 years of age, inclusive (consent of parent/legal guardian required)
  • Documented chronic infection
  • HBeAg positive or HBeAg negative
  • Weight > 35 kg
  • Able to swallow oral tablets
  • HBV DNA > 100,000 copies/mL (polymerase chain reaction (PCR) method)
  • (ALT) > 2 × (ULN) at screening, OR any history of ALT > 2 × ULN over the past 24 months
  • Willing and able to provide written /assent (child and parent/legal guardian)
  • Negative serum pregnancy test (for postmenarchal females only)
  • Estimated ( [using the Schwartz formula]) > 80 mL/min/1.73m\^2
  • Adequate hematologic function ( ≥ 1,500/mm\^3; ≥ 10.0 g/dL)
  • No prior TDF therapy (participants may have received prior interferon or oral anti-HBV nucleoside/nucleotide therapy; participants must have discontinued interferon therapy ≥ 6 months prior to screening; participants experienced on anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)

Exclusion criteria

Exclusion Criteria

  • Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study
  • Males and females of who are not willing to use an effective method of during the study
  • Decompensated liver disease
  • Receipt of interferon (pegylated or not) therapy within 6 months of the Screening Visit
  • Receipt of anti- nucleoside/nucleotide therapy within 16 weeks of the Screening Visit
  • Alpha fetoprotein > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Coinfection with , virus (HCV), or hepatitis D virus (HDV)
  • History of significant renal disease (eg, nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
  • History of significant bone disease (eg, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses, multiple bone fractures)
  • Significant cardiovascular, pulmonary, or neurological disease
  • Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
  • History of solid organ or bone marrow transplantation
  • Ongoing therapy with nephrotoxic agents, competitors of renal excretion, systemic chemotherapeutic agents, systemic , interleukin-2 (IL-2), or other immunomodulating or agents
  • Known to the study drugs, the metabolites or formulation
  • Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the participants unsuitable for the study or unable to comply with dosing requirements
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Tenofovir disoproxil fumarate (TDF)

    Drug: Tenofovir disoproxil fumarate (TDF)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72

    The percentage of participants with HBV DNA \< 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm. In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.

    Time frame: Week 72

  2. Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72

    Data were summarized by treatment and age group (grouped by baseline age for analysis). In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Weeks 48, 96, 144, and 192

  2. Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Weeks 48, 72, 96, 144, and 192

  3. Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Weeks 48, 72, 96, 144, and 192

  4. Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Weeks 48, 72, 96, 144, and 192

  5. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  6. Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192

    HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  7. Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192

    The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Weeks 48, 96, 144, and 192

  8. Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192

    The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  9. Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 48

  10. Percent Change From Baseline in Spine BMD at Week 72

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 72

  11. Percent Change From Baseline in Spine BMD at Week 96

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 96

  12. Percent Change From Baseline in Spine BMD at Week 144

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 144

  13. Percent Change From Baseline in Spine BMD at Week 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 192

  14. Percent Change From Baseline in Whole Body BMD at Week 48

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 48

  15. Percent Change From Baseline in Whole Body BMD at Week 72

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 72

  16. Percent Change From Baseline in Whole Body BMD at Week 96

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 96

  17. Percent Change From Baseline in Whole Body BMD at Week 144

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 144

  18. Percent Change From Baseline in Whole Body BMD at Week 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 192

  19. Change From Baseline in Z-score for Spine BMD at Week 48

    To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 48

  20. Change From Baseline in Z-score for Spine BMD at Week 72

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 72

  21. Change From Baseline in Z-score for Spine BMD at Week 96

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 96

  22. Change From Baseline in Z-score for Spine BMD at Week 144

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 144

  23. Change From Baseline in Z-score for Spine BMD at Week 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 192

  24. Change From Baseline in Z-score for Whole Body BMD at Week 48

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 48

  25. Change From Baseline in Z-score for Whole Body BMD at Week 72

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 72

  26. Change From Baseline in Z-score for Whole Body BMD at Week 96

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 96

  27. Change From Baseline in Z-score for Whole Body BMD at Week 144

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 144

  28. Change From Baseline in Z-score for Whole Body BMD at Week 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis).

    Time frame: Baseline; Week 192

  29. Number of Participants With Changes in Drug-Resistant Mutations During the Study

    The number of participants with changes in drug-resistant mutations during the study was summarized.

    Time frame: Baseline through Week 192

  30. Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  31. Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  32. Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  33. Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  34. Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

  35. Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

    Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

    Time frame: Baseline; Weeks 48, 72, 96, 144, and 192

08

Results

Posted Nov 7, 2012

Participant flow

Participants were enrolled at 3 sites in the United States, 8 sites in Poland, 3 sites in Romania, 2 sites in Bulgaria, 2 sites in France, 2 sites in Spain, and 1 site in Turkey. The first participant was screened on 03 December 2008. The last study visit occurred on 02 December 2015.

Randomized Phase (Through Week 72)
Participant flow — Randomized Phase (Through Week 72)
MilestoneTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 Years
Started10421341
Completed10411337
Not completed0104
Withdrew: Investigator's discretion0102
Withdrew: Per protocol alt elevation0002
Open-Label Phase
Participant flow — Open-Label Phase
MilestoneTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 Years
Started10411339
Completed7391236
Not completed3213
Withdrew: Safety, tolerability or efficacy reasons1000
Withdrew: Withdrew consent1011
Withdrew: Lost to follow-up1201
Withdrew: Did not meet entrance criteria0001

Outcome measures

PrimaryPercentage of Participants With HBV DNA < 400 Copies/mL at Week 72

The percentage of participants with HBV DNA \< 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm. In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 7290.088.10088.50
Statistical analysis
  • TDF 12-14 Years vs TDF 15-17 Years vs Placebo 12-14 Years vs Placebo 15-17 Years · Cochran-Mantel-Haenszel · p = < 0.001 (A p-value of \< 0.05 was considered statistically significant.)
PrimaryPercentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis). In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.

Time frame:
Baseline to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 7202.4001.90
SecondaryPercentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Weeks 48, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4890.085.70086.50
Week 9690.088.153.868.388.564.8
Week 144100.090.569.285.492.381.5
Week 19290.085.776.973.286.574.1
SecondaryPercentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4870.076.230.826.875.027.8
Week 7280.076.230.841.576.938.9
Week 9680.076.269.265.976.966.7
Week 14460.071.469.275.669.274.1
Week 19280.071.484.675.673.177.8
SecondaryPercentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4870.069.00069.20
Week 7280.069.00071.20
Week 9680.073.846.251.275.050.0
Week 14460.069.053.868.367.364.8
Week 19280.064.369.263.467.364.8
SecondaryPercentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4880.081.00080.80
Week 7290.083.30084.60
Week 9690.088.153.863.488.561.1
Week 14490.088.169.282.988.579.6
Week 19290.083.376.973.284.674.1
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 48000000
Week 7202.4001.90
Week 9602.4001.90
Week 14402.4001.90
Week 19202.4001.90
SecondaryPercentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192

HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 48000000
Week 7202.4001.90
Week 9602.4001.90
Week 14402.4001.90
Week 192000000
SecondaryPercentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192

The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Weeks 48, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 48000000
Week 9602.4001.90
Week 14402.4001.90
Week 19204.804.93.83.7
SecondaryPercentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192

The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 48000000
Week 72000000
Week 96000000
Week 1440002.401.9
Week 1920002.401.9
SecondaryPercent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 489.234 ± 3.47822.114 ± 3.60239.038 ± 6.65754.435 ± 4.90913.510 ± 4.55075.562 ± 5.6772
SecondaryPercent Change From Baseline in Spine BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 72
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 72
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Spine BMD at Week 7211.516 ± 3.88183.589 ± 4.563314.131 ± 9.95636.117 ± 6.06245.144 ± 5.42918.080 ± 7.8996
SecondaryPercent Change From Baseline in Spine BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 96
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 96
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Spine BMD at Week 9613.811 ± 4.67124.196 ± 4.802116.687 ± 10.43594.272 ± 7.04636.119 ± 6.12007.003 ± 9.3658
SecondaryPercent Change From Baseline in Spine BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 144
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 144
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Spine BMD at Week 14419.224 ± 8.75945.289 ± 5.808421.346 ± 13.47096.144 ± 8.32868.133 ± 8.56119.311 ± 11.3262
SecondaryPercent Change From Baseline in Spine BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 192
Reported as:
Mean · percentage change
Percent Change From Baseline in Spine BMD at Week 192
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Spine BMD at Week 19223.933 ± 8.51666.673 ± 7.287025.036 ± 14.23466.867 ± 9.373610.050 ± 10.163711.212 ± 13.1459
SecondaryPercent Change From Baseline in Whole Body BMD at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percent Change From Baseline in Whole Body BMD at Week 48
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Whole Body BMD at Week 485.123 ± 3.83091.339 ± 1.93245.470 ± 3.49583.236 ± 2.85732.048 ± 2.78303.817 ± 3.1576
SecondaryPercent Change From Baseline in Whole Body BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 72
Reported as:
Mean · percentage change
Percent Change From Baseline in Whole Body BMD at Week 72
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Whole Body BMD at Week 727.282 ± 3.91562.141 ± 2.62848.480 ± 4.47704.335 ± 3.40733.067 ± 3.48195.391 ± 4.0902
SecondaryPercent Change From Baseline in Whole Body BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 96
Reported as:
Mean · percentage change
Percent Change From Baseline in Whole Body BMD at Week 96
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Whole Body BMD at Week 968.034 ± 3.49733.023 ± 3.206310.056 ± 5.42964.291 ± 4.31953.943 ± 3.77305.675 ± 5.1858
SecondaryPercent Change From Baseline in Whole Body BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 144
Reported as:
Mean · percentage change
Percent Change From Baseline in Whole Body BMD at Week 144
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Whole Body BMD at Week 14410.940 ± 4.88193.529 ± 3.173412.638 ± 5.99734.730 ± 5.22134.949 ± 4.57536.505 ± 6.2944
SecondaryPercent Change From Baseline in Whole Body BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 192
Reported as:
Mean · percentage change
Percent Change From Baseline in Whole Body BMD at Week 192
percentage changeTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Percent Change From Baseline in Whole Body BMD at Week 19213.923 ± 4.61394.295 ± 3.731814.797 ± 6.49934.549 ± 5.44946.086 ± 5.40297.223 ± 7.2666
SecondaryChange From Baseline in Z-score for Spine BMD at Week 48

To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 48
Reported as:
Mean · z-score
Change From Baseline in Z-score for Spine BMD at Week 48
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Spine BMD at Week 480.02 ± 0.247-0.10 ± 0.2550.04 ± 0.3930.05 ± 0.322-0.08 ± 0.2560.05 ± 0.337
SecondaryChange From Baseline in Z-score for Spine BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 72
Reported as:
Mean · z-score
Change From Baseline in Z-score for Spine BMD at Week 72
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Spine BMD at Week 72-0.10 ± 0.312-0.05 ± 0.3250.09 ± 0.4980.10 ± 0.339-0.06 ± 0.3200.10 ± 0.378
SecondaryChange From Baseline in Z-score for Spine BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 96
Reported as:
Mean · z-score
Change From Baseline in Z-score for Spine BMD at Week 96
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Spine BMD at Week 96-0.19 ± 0.365-0.07 ± 0.356-0.02 ± 0.498-0.13 ± 0.414-0.10 ± 0.357-0.11 ± 0.431
SecondaryChange From Baseline in Z-score for Spine BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 144
Reported as:
Mean · z-score
Change From Baseline in Z-score for Spine BMD at Week 144
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Spine BMD at Week 144-0.20 ± 0.560-0.05 ± 0.417-0.16 ± 0.625-0.04 ± 0.405-0.08 ± 0.447-0.06 ± 0.455
SecondaryChange From Baseline in Z-score for Spine BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 192
Reported as:
Mean · z-score
Change From Baseline in Z-score for Spine BMD at Week 192
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Spine BMD at Week 192-0.24 ± 0.5180.08 ± 0.544-0.26 ± 0.654-0.05 ± 0.5040.02 ± 0.548-0.10 ± 0.543
SecondaryChange From Baseline in Z-score for Whole Body BMD at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 48
Reported as:
Mean · z-score
Change From Baseline in Z-score for Whole Body BMD at Week 48
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Whole Body BMD at Week 480.02 ± 0.426-0.15 ± 0.2570.10 ± 0.3700.04 ± 0.308-0.12 ± 0.2980.05 ± 0.322
SecondaryChange From Baseline in Z-score for Whole Body BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 72
Reported as:
Mean · z-score
Change From Baseline in Z-score for Whole Body BMD at Week 72
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Whole Body BMD at Week 720.02 ± 0.398-0.19 ± 0.3380.20 ± 0.4500.06 ± 0.306-0.16 ± 0.3550.09 ± 0.349
SecondaryChange From Baseline in Z-score for Whole Body BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 96
Reported as:
Mean · z-score
Change From Baseline in Z-score for Whole Body BMD at Week 96
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Whole Body BMD at Week 96-0.12 ± 0.294-0.19 ± 0.4510.09 ± 0.528-0.06 ± 0.432-0.18 ± 0.424-0.03 ± 0.456
SecondaryChange From Baseline in Z-score for Whole Body BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 144
Reported as:
Mean · z-score
Change From Baseline in Z-score for Whole Body BMD at Week 144
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Whole Body BMD at Week 144-0.27 ± 0.431-0.21 ± 0.473-0.06 ± 0.554-0.16 ± 0.468-0.22 ± 0.462-0.14 ± 0.484
SecondaryChange From Baseline in Z-score for Whole Body BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis).

Time frame:
Baseline; Week 192
Reported as:
Mean · z-score
Change From Baseline in Z-score for Whole Body BMD at Week 192
z-scoreTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Change From Baseline in Z-score for Whole Body BMD at Week 192-0.34 ± 0.499-0.11 ± 0.524-0.21 ± 0.486-0.19 ± 0.517-0.16 ± 0.521-0.19 ± 0.504
SecondaryNumber of Participants With Changes in Drug-Resistant Mutations During the Study

The number of participants with changes in drug-resistant mutations during the study was summarized.

Time frame:
Baseline through Week 192
Reported as:
Number · participants
Number of Participants With Changes in Drug-Resistant Mutations During the Study
participantsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
New TDF Drug-Resistant Mutations00
Enrichment of TDF Drug-Resistant Mutations00
SecondaryPercentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4811.117.97.78.616.78.3
Week 7211.123.123.111.420.814.6
Week 9644.430.838.528.633.331.3
Week 14444.438.553.834.339.639.6
Week 19233.343.653.837.141.741.7
SecondaryPercentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4811.115.47.78.614.68.3
Week 7211.123.123.111.420.814.6
Week 9644.430.838.525.733.329.2
Week 14433.338.553.834.337.539.6
Week 19233.338.553.837.137.541.7
SecondaryPercentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4811.112.80012.50
Week 7211.115.40014.60
Week 9644.428.230.822.931.325.0
Week 14422.230.846.225.729.231.3
Week 19233.328.246.225.729.231.3
SecondaryPercentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4885.771.411.121.274.319.0
Week 7285.771.422.233.374.331.0
Week 9685.778.666.763.680.064.3
Week 14457.171.466.772.768.671.4
Week 19285.775.077.869.777.171.4
SecondaryPercentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4885.771.40074.30
Week 7285.771.40074.30
Week 9685.778.655.654.580.054.8
Week 14457.171.466.769.768.669.0
Week 19285.767.977.857.671.461.9
SecondaryPercentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.

Time frame:
Baseline; Weeks 48, 72, 96, 144, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
percentage of participantsTDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal TDF 12-17 YearsTotal Placebo 12-17 Years
Week 4816.718.50018.20
Week 7216.722.20021.20
Week 9650.033.333.324.236.426.2
Week 14433.329.655.627.330.333.3
Week 19250.029.655.627.333.333.3

Adverse events

Collected over Baseline through end of the Open-Label Phase (up to 4 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind TDF—5/52 (9.6%)34/52 (65.4%)
Double-Blind Placebo—11/54 (20.4%)40/54 (74.1%)
Open-Label TDF-TDF—8/51 (15.7%)30/51 (58.8%)
Open-Label Placebo-TDF—10/52 (19.2%)31/52 (59.6%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventDouble-Blind TDFDouble-Blind PlaceboOpen-Label TDF-TDFOpen-Label Placebo-TDF
HepatitisHepatobiliary disorders1/527/541/510/52
Alanine aminotransferase increasedInvestigations0/521/540/513/52
Ventricular extrasystolesCardiac disorders0/520/541/510/52
Abdominal painGastrointestinal disorders0/521/541/511/52
Peptic ulcer perforationGastrointestinal disorders0/520/541/510/52
Patella fractureInjury, poisoning and procedural complications0/520/541/510/52
Blood creatinine increasedInvestigations0/520/541/510/52
Glucose urine presentInvestigations0/520/541/510/52
Protein urine presentInvestigations0/520/541/510/52
DepressionPsychiatric disorders0/520/541/510/52
Most frequent other events
Showing 10 of 28
Most frequent other events
EventDouble-Blind TDFDouble-Blind PlaceboOpen-Label TDF-TDFOpen-Label Placebo-TDF
PharyngitisInfections and infestations15/5211/549/5113/52
NasopharyngitisInfections and infestations5/5212/546/5112/52
AcneSkin and subcutaneous tissue disorders2/5210/542/516/52
Abdominal painGastrointestinal disorders3/527/541/519/52
HeadacheNervous system disorders2/529/541/512/52
Upper respiratory tract infectionInfections and infestations5/527/543/517/52
BronchitisInfections and infestations2/521/546/514/52
GastroenteritisInfections and infestations2/522/540/515/52
RhinitisInfections and infestations5/523/543/511/52
LymphadenopathyBlood and lymphatic system disorders0/525/541/510/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Mean13.3 ± 0.8216.1 ± 0.7513.2 ± 0.6915.9 ± 0.8215.4 ± 1.38
Sex: Female, Male
Sex: Female, Male(Participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Female31141533
Male73192673
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Asian01102
Black01001
White1039123798
Other01045
Region of Enrollment
Region of Enrollment(participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Bulgaria03317
France01012
Poland63163174
Romania442414
Spain00022
Turkey01102
United States02125
Region of Enrollment
Region of Enrollment(participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Europe10401239101
North America02125
Alanine aminotransferase (ALT) level at baseline
Alanine aminotransferase (ALT) level at baseline(U/L)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Mean77 ± 54.8106 ± 116.4101 ± 95.4101 ± 89.5101 ± 98.5
ALT normal at baseline
ALT normal at baseline(participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Normal3144829
Abnormal72893377
HBV Genotype
HBV Genotype(participants)TDF 12-14 YearsTDF 15-17 YearsPlacebo 12-14 YearsPlacebo 15-17 YearsTotal
Genotype A53052969
Genotype B01113
Genotype C01001
Genotype D51071133

2 further baseline measures are reported on the registry.

09

Study locations

21 sites
  • Children's Hospital & Research Center at Oakland
    Oakland, California 94609, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Children's Hospital & Regional Medical Center, d/b/a Seattle Children's Research Institute
    Seattle, Washington 98105, United States
  • Multiprofile Hospital for Active Treatment Sveti Georgi
    Plovdiv, 4002, Bulgaria
  • Clinic of Gastroenterology, Specialized Hospital for Active Treatment of Pediatric Diseases, Sofia
    Sofia, 1606, Bulgaria
  • Hopital Femmes Meres Enfants
    Bron Cedex, 69677, France
  • Hôpital Claude Huriez
    Lille Cedex, 59037, France
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny Akademii Medycznej w Bialymstoku
    Białystok, 15-274, Poland
  • Wojewodzki Specjalistyczny Szpital im Bieganskiego
    Bydgoszcz, 85-030, Poland
  • Wojewodzki Szpital Obserwacyjno-Zakazny im. T. Browicza
    Bydgoszcz, 85-030, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawla II
    Kraków, 31-202, Poland
  • Samodzielny Publiczny Szpital Kliniczny im. Karola Johschera
    Poznan, 60-572, Poland
  • Specjalistyczny Zespol Opieki Zdrowotnej nad Matka i Dzieckiem
    Poznań, 61-734, Poland
  • Wojewodzki Szpital Zakazny
    Warszawa, 01-201, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Wrocław, 50-368, Poland
  • Fundeni Clinical Institute
    Bucharest, 022328, Romania
  • Institute for Infectious Diseases
    Bucharest, 21105, Romania
  • Cluj Childrens Emergency Hospital
    Napaco, 400217, Romania
  • Hosp Univ y Politecnico La Fe de Valencia
    Madrid, 28046, Spain
  • Hospital Universitario De Getafe
    Madrid, 46009, Spain
  • Ege Universitesi Tip Fakultesi Hastanesi
    Izmir, 35100, Turkey
10

References and documents

Publications

  • Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012 Dec;56(6):2018-26. doi: 10.1002/hep.25818. Epub 2012 Aug 27. PubMed 22544804 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Mar 2011 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 8 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 14, 2008
Start
Dec 2008
Primary completionActual
Mar 2011
CompletionActual
Dec 2015
Results delay requested
Apr 16, 2012
Results first posted
Nov 7, 2012
Last update
Sep 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00734162
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Dec 2008
Primary completion
Mar 2011
Completion
Dec 2015
Results posted
Nov 7, 2012
Last update
Sep 1, 2016

Study contacts

Benedetta Massetto, MD, PhD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion